{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.6","upperLimit":"11.8","value":"2.23"},{"groupId":"OG001","lowerLimit":"1.8","upperLimit":"9.5","value":"2.09"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"Time to Response (TTR) for participants demonstrating a response (either CR or PR) was defined as the time from the date of randomization to the date of the first confirmed response. CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm.; PR = At least a 30% decrease in the sum of diameters of target lesions, taking, as reference, the baseline sum diameters.","dispersionType":"Full Range","groups":[{"description":"Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.","id":"OG000","title":"Nivolumab"},{"description":"Docetaxel 75mg/m\\^2 solution intravenously every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or study ends.","id":"OG001","title":"Docetaxel"}],"paramType":"MEDIAN","populationDescription":"All confirmed responders (participants demonstrating CR or PR)","reportingStatus":"POSTED","timeFrame":"From the date of randomization to the date of the first confirmed response, up to approximately 12 months","title":"Time To Response (TTR) in Months for All Confirmed Responders","type":"SECONDARY","unitOfMeasure":"Months"}